^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    BCR (BCR Activator Of RhoGEF And GTPase)

    i
    Other names: BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL
    4d
    Response-adapted dasatinib de-escalation strategy compared to upfront Low-dose dasatinib: A prospective cohort study. (PubMed, Leuk Res)
    Dasatinib de-escalation after 100 mg standard dose achieved superior early response, fewer discontinuations, and sustained outcomes versus upfront low-dose therapy. This first Indian study supports de-escalation as an effective, real-world dose-optimization strategy.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    dasatinib
    4d
    A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=12, Completed, CRISPR Therapeutics | Recruiting --> Completed | N=290 --> 12 | Trial completion date: Nov 2030 --> Mar 2026 | Trial primary completion date: May 2030 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CTX131
    6d
    Diplopia and bilateral optic disc swelling as the initial presentation of B-lymphoblastic lymphoma: a case report. (PubMed, Front Oncol)
    Subsequently, he was started on systemic therapy with dasatinib in combination with the HyperCVAD chemotherapy regimen...Ocular features such as diplopia in the setting of chronic unexplained headache should prompt careful fundus examination, as it may reveal critical clues to underlying intracranial pathology. Early neuroimaging, timely biopsy, and rapid initiation of systemic therapy remain critical for optimizing outcomes.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    BCR-ABL1 fusion
    |
    dasatinib
    6d
    ELVN-001-101: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia (clinicaltrials.gov)
    P1, N=250, Recruiting, Enliven Therapeutics | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    ABL1 T315I
    |
    ELVN-001
    6d
    SPON - 1751-19: EWALL-PH-03: An open label, 2-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib plus Chemotherapy with Imatinib plus Chemotherapy as front-line therapy for patients aged 55 years and over with Philadelphia chromosome positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL) (2023-505330-95-01)
    P1/2, N=100, Recruiting, Cardiff University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    imatinib • Iclusig (ponatinib) • Blincyto (blinatumomab)
    6d
    ASC4CN: Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Scemblix (asciminib)
    7d
    Leukemia Diagnosis 2.0: Revolutionizing advanced and Futuristic Point-of-Care Detection and Monitoring. (PubMed, Crit Rev Oncol Hematol)
    These platforms enable rapid, multiplexed biomarker analysis of fusion genes (BCR-ABL, PML-RARA), surface antigens (CD33/CD34), exosomes, and CTCs for minimally invasive leukemia detection, MRD monitoring, and remote management. Covering principles, material advances, clinical applications, and prospects, this work highlights their potential to revolutionize accessible, precise, timely global leukemia care.
    Review • Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD33 (CD33 Molecule) • PML (Promyelocytic Leukemia) • CD34 (CD34 molecule)
    8d
    Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (clinicaltrials.gov)
    P3, N=348, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    ABL1 T315I
    |
    dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • vincristine • mesna • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    8d
    Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) (clinicaltrials.gov)
    P2, N=25, Suspended, University of Chicago | Recruiting --> Suspended
    Trial suspension
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
    |
    dasatinib • Iclusig (ponatinib) • Besponsa (inotuzumab ozogamicin) • vincristine
    11d
    A041703: Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=84, Recruiting, National Cancer Institute (NCI) | N=64 --> 84
    Enrollment change
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Iclusig (ponatinib) • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    11d
    BREATHS: In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, University College, London | Trial primary completion date: Apr 2026 --> Jul 2026
    Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • ICOS (Inducible T Cell Costimulator)
    11d
    Targeting Mitochondrial Vulnerabilities in Chronic Myeloid Leukemia: From Pathobiology to Novel Therapeutic Opportunities. (PubMed, Cancers (Basel))
    Mitochondria emerge as central regulators of CML pathobiology. Therapeutic strategies targeting mitochondrial metabolism, redox homeostasis, and apoptotic signaling pathways represent promising approaches to overcoming TKI resistance and may improve clinical outcomes for patients with CML.
    Review • Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)